Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard

Nicolas Mottet; Maria De Santis; Erik Briers; Liam Bourke; Silke Gillessen; Jeremy P Grummet; Thomas B Lam; Henk G van der Poel; Olivier Rouvière; Roderick C N van den Bergh; Philip Cornford

doi:10.1016/j.eururo.2017.09.029

Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard

Nicolas Mottet, Maria De Santis, Erik Briers, Liam Bourke, Silke Gillessen, Jeremy P Grummet, Thomas B Lam, Henk G van der Poel, Olivier Rouvière, Roderick C N van den Bergh, Philip Cornford

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Commentary/debate › peer-review

Abstract

Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.

Original language	English
Journal	European Urology
Early online date	2 Nov 2017
DOIs	https://doi.org/10.1016/j.eururo.2017.09.029
Publication status	E-pub ahead of print - 2 Nov 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2017.09.029

Cite this

Mottet, N., De Santis, M., Briers, E., Bourke, L., Gillessen, S., Grummet, J. P., Lam, T. B., van der Poel, H. G., Rouvière, O., van den Bergh, R. C. N., & Cornford, P. (2017). Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. European Urology. Advance online publication. https://doi.org/10.1016/j.eururo.2017.09.029

@article{e9f54b3a57024484a7b1532be6e8d2ed,

title = "Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard",

abstract = "Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.",

author = "Nicolas Mottet and {De Santis}, Maria and Erik Briers and Liam Bourke and Silke Gillessen and Grummet, {Jeremy P} and Lam, {Thomas B} and {van der Poel}, {Henk G} and Olivier Rouvi{\`e}re and {van den Bergh}, {Roderick C N} and Philip Cornford",

year = "2017",

month = nov,

day = "2",

doi = "10.1016/j.eururo.2017.09.029",

language = "English",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer

T2 - Abiraterone Acetate Combined with Castration Is Another Standard

AU - Mottet, Nicolas

AU - De Santis, Maria

AU - Briers, Erik

AU - Bourke, Liam

AU - Gillessen, Silke

AU - Grummet, Jeremy P

AU - Lam, Thomas B

AU - van der Poel, Henk G

AU - Rouvière, Olivier

AU - van den Bergh, Roderick C N

AU - Cornford, Philip

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.

AB - Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.

U2 - 10.1016/j.eururo.2017.09.029

DO - 10.1016/j.eururo.2017.09.029

M3 - Commentary/debate

C2 - 29103760

SN - 0302-2838

JO - European Urology

JF - European Urology

ER -

Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this